“Salarius is now fully compliant with all Nasdaq listing requirements, marking another critical step in our planned merger with Decoy Therapeutics,” said Mark J. Rosenblum, acting CEO and CFO of ...
Tagraxofusp demonstrated a manageable safety profile but limited efficacy in CMML patients, with stable disease as the best ...